MEDICAL SECTOR: diagnostic and therapeutic sensors.
Medical sensors represent the combination of electronics, material sciences and information technology, with the application of micro- and nanotechnology to develop cutting-edge sensors and devices. These innovative elements also enable biomedicine to face new challenges and break new grounds.
Optoi medical division develops optical devices for diagnostic and therapeutic applications.
The Group employs a cross-functional team to create solutions aimed at simplifying and making more reliable the detection of circulating biomolecules, providing valid support to medical staff and biopharmaceuticals. Optoi collaborates with local, national, and international research bodies and is involved in several projects at the European level.
Optoi medical division develops optical devices for diagnostic and therapeutic applications.
The Group employs a cross-functional team to create solutions aimed at simplifying and making more reliable the detection of circulating biomolecules, providing valid support to medical staff and biopharmaceuticals. Optoi collaborates with local, national, and international research bodies and is involved in several projects at the European level.
Projects under development
EU funding H2020-MSCA-RISE-2020.
Acronym: diaRNAgnosis. Title: A novel platform for the direct profiling of circulating cell-free ribonucleic acids in biofluids. Consortium leader: DGSL (Spain). GA No 101007934.
An international consortium, led by DESTINA Genomica S.L., combines the transversal skills of companies and universities from Spain, Italy, and the Netherlands. The diaRNAgnosis project aims to create reliable and selective diagnostic tools for detecting circulating cell-free (ccf) RNA in liquid biopsy samples of prostate cancer and germ cell tumours in the testicles.
An international consortium, led by DESTINA Genomica S.L., combines the transversal skills of companies and universities from Spain, Italy, and the Netherlands. The diaRNAgnosis project aims to create reliable and selective diagnostic tools for detecting circulating cell-free (ccf) RNA in liquid biopsy samples of prostate cancer and germ cell tumours in the testicles.
CARITRO FOUNDATION
An innovative diagnostic device for the measurement of microRNAs in liquid biopsies. Consortium leader: University of Trento – CIBIO (Italy).
Optoi has been actively collaborating with the University of Trento – CIBIO for some years now. Thanks to this project, CIBIO, together with the Healthcare Trust of the Autonomous Province of Trento (APSS), will analyse microRNAs as potential predictors of the efficacy of abiraterone in patients with prostate cancer using conventional analytical systems and optical sensors developed by Optoi.
Optoi has been actively collaborating with the University of Trento – CIBIO for some years now. Thanks to this project, CIBIO, together with the Healthcare Trust of the Autonomous Province of Trento (APSS), will analyse microRNAs as potential predictors of the efficacy of abiraterone in patients with prostate cancer using conventional analytical systems and optical sensors developed by Optoi.
EU funding H2020-SC1-BHC-2018-2020.
Acronym: ARREST-TB. Title: Accurate, Rapid, Robust and Economical diagnostic technologies for Tuberculosis. Consortium leader: The University of Edinburgh (UK). GA No 825931.
Optoi is part of an international consortium of universities and companies from Italy, the United Kingdom and Spain, led by the University of Edinburgh and dedicated to the development of diagnostic technologies for tuberculosis, in collaboration with the Research Institute of Tuberculosis in Moscow and with two other reference centres in India that deal with clinical
The ARREST-TB (Accurate, Rapid, Robust and Economical diagnoStic Technologies for Tuberculosis) project aims to develop innovative technologies that can contribute to the early diagnosis of tuberculosis with trials in India and Russia.
Optoi - with its partner DESTINA Genomica - develops an innovative diagnostic system based on optoelectronic sensors and selective chemistry, measuring new generation biomarkers - microRNA - for the early diagnosis and therapeutic monitoring of Tuberculosis.
Optoi is part of an international consortium of universities and companies from Italy, the United Kingdom and Spain, led by the University of Edinburgh and dedicated to the development of diagnostic technologies for tuberculosis, in collaboration with the Research Institute of Tuberculosis in Moscow and with two other reference centres in India that deal with clinical
The ARREST-TB (Accurate, Rapid, Robust and Economical diagnoStic Technologies for Tuberculosis) project aims to develop innovative technologies that can contribute to the early diagnosis of tuberculosis with trials in India and Russia.
Optoi - with its partner DESTINA Genomica - develops an innovative diagnostic system based on optoelectronic sensors and selective chemistry, measuring new generation biomarkers - microRNA - for the early diagnosis and therapeutic monitoring of Tuberculosis.
Completed projects
EU funding H2020 Marie-Curie Actions.
Accordion EU funding H2020 Marie-Curie Actions. Acronym: miRNA-DisEASY. Title: microRNA biomarkers in an innovative biophotonic sensor kit for high-specific diagnosis. Consortium leader: OPTOI Srl. (Italy). GA No 690866.
A multidisciplinary and cross-sectoral consortium led by Optoi has synergistically involved companies and academic institutions in Germany, Spain, Italy, and Brazil with the mutual exchange of highly qualified personnel. The research generated a stimulating scientific and technological environment that was instrumental in sparking new ideas and technological solutions for lung cancer diagnosis.
As part of the miRNA-DisEASY project, Optoi has developed a device alongside revolutionary chemical technology intended to simplify and make the detection of circulating biomarkers more reliable, providing valuable support to medical staff.
At the end of the project, OPTOI was awarded the title of “key innovators” by “Innovation Radar”, a European Commission initiative.
A multidisciplinary and cross-sectoral consortium led by Optoi has synergistically involved companies and academic institutions in Germany, Spain, Italy, and Brazil with the mutual exchange of highly qualified personnel. The research generated a stimulating scientific and technological environment that was instrumental in sparking new ideas and technological solutions for lung cancer diagnosis.
As part of the miRNA-DisEASY project, Optoi has developed a device alongside revolutionary chemical technology intended to simplify and make the detection of circulating biomarkers more reliable, providing valuable support to medical staff.
At the end of the project, OPTOI was awarded the title of “key innovators” by “Innovation Radar”, a European Commission initiative.
Publications
- E Garcia-Fernandez, et. al. miR-122 direct detection in human serum by time-gated fluorescence imaging. Chemical Communications, 2019, 55 (99), 14958-14961.
- S Detassis, et. al. New Platform for the Direct Profiling of microRNAs in Biofluids. Analytical Chemistry, 2019, 91 (9), 5874-5880.
- S Detassis, et. al. New Platform for the Direct Profiling of microRNAs in Biofluids. Best Poster Award at the Oligonucleotide Therapeutic Society annual meeting, 2019.